EpiVax, Inc.

EpiVax has been providing immunogenicity expertise for over 25 years, helping pharmaceutical and biotech teams generate the insights they need to make informed decisions across biologic and vaccine programs. Our work ensures the success of pipelines at every stage, supporting companies ranging from emerging startups to global industry leaders.  We take a risk-based, fit-for-purpose approach to immunogenicity assessment, helping developers focus on what matters most during each phase. From early discovery through regulatory submission and beyond, we integrate computational analyses, experimental in vitro assays, and expert consulting to generate actionable data that informs downstream development and regulatory strategies, mitigates risk, preserves resources, and strengthens confidence in program decisions.  Our goal is to equip developers with the tools and insights needed to successfully advance safer and more effective treatments worldwide. As EpiVax continues to expand our capabilities, partnerships, and team of scientists, we’re stepping into a healthier future for all.